Artwork

Content provided by OncoPharmPod and John Bossaer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OncoPharmPod and John Bossaer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Repotrectinib & Capivasertib

23:49
 
Share
 

Manage episode 385461964 series 1848091
Content provided by OncoPharmPod and John Bossaer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OncoPharmPod and John Bossaer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
  continue reading

340 episodes

Artwork

Repotrectinib & Capivasertib

OncoPharm

58 subscribers

published

iconShare
 
Manage episode 385461964 series 1848091
Content provided by OncoPharmPod and John Bossaer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by OncoPharmPod and John Bossaer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
  continue reading

340 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide